Use of VEGF antagonists for treating angiogenic eye disorders

A novel dosing regimen for VEGF antagonists in neovascular eye diseases, with less frequent administration intervals, addresses the need for more efficient treatment by maintaining efficacy and improving patient compliance.

JP2025169389APending Publication Date: 2025-11-12REGENERON PHARMACEUTICALS INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2025136675
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2011-11-21
Filing Date
2025-08-20
Publication Date
2025-11-12

AI Technical Summary

Technical Problem

Current dosing regimens for neovascular eye diseases, such as AMD and CRVO, require frequent administration of VEGF antagonists, which can be burdensome for patients and may not be optimal in terms of efficacy.

Method used

A dosing regimen involving an initial dose followed by secondary and tertiary doses of VEGF antagonists administered at specific intervals, allowing for less frequent administration over an extended period, such as once every 8 weeks, to maintain efficacy.

Benefits of technology

This regimen provides effective treatment for neovascular eye diseases with reduced frequency of injections, improving patient compliance and potentially enhancing treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025169389000003
    Figure 2025169389000003
  • Figure 2025169389000001
    Figure 2025169389000001
  • Figure 2025169389000002
    Figure 2025169389000002
Patent Text Reader

Abstract

To provide dosing regimens for angiogenic eye disorders, particularly regimens that allow less frequent dosing while maintaining high levels of efficacy.SOLUTION: The present invention provides a method of treating an angiogenic eye disorder by sequentially administering multiple dosing of a VEGF antagonist to a patient. The method comprises administering to the patient multiple dosing of the VEGF antagonist at a frequency of once every 8 weeks or once every more weeks. The method is useful for treating angiogenic eye disorders such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and corneal neovascularization.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Method for treating intraocular neovascular diseases

    US20070190058A1

  • Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths

    US7300563B2

  • Methods of treating eye disorders with modified chimeric polypeptides

    US7303746B2

  • Method of treating eye injury with local administration of a VEGF inhibitor

    US7303748B2

  • Use of VEGF inhibitors for treatment of eye disorders

    US7306799B2